Access the full text.
Sign up today, get DeepDyve free for 14 days.
MD Obeso, MD Luquin, MD Lage, Disease Obeso (1986)
Intravenous lisuride corrects oscillations of motor performance in Parkinson's diseaseAnnals of Neurology, 19
M. Hoehn, R. Elton (1985)
Low dosages of bromocriptine added to levodopa in Parkinson's diseaseNeurology, 35
C. Marsden, J. Parkes (1977)
SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASEThe Lancet, 309
P. Teychenné, M. Ziegler, C. Lake, S. Enna (1982)
Low CSF GABA in parkinsonian patients who respond poorly to therapy or suffer from the “on‐off” phenomenonAnnals of Neurology, 11
B. Djahanguiri, S. Hemmati, D. Sadeghi, A. Firouzabadi (1967)
The prevention of acute gastric ulcer in the rat by alpha-methyldopa.Medicina et pharmacologia experimentalis. International journal of experimental medicine, 17 5
On - off response : clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients
K. Bergmann, J. Limongi, Y. Lowe, M. Mendoza, M. Yahr (1984)
POTENTIATION OF THE "DOPA" EFFECT IN PARKINSONISM BY A DIRECT GABA RECEPTOR AGONISTThe Lancet, 323
J. Nutt, W. Woodward, J. Hammerstad, J. Carter, John Anderson (1984)
The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.The New England journal of medicine, 310 8
D. Chicot, R. Wright, B. Brotman, A. Prince (1975)
HEPANOSTICON IN SCREENING FOR HBsAgThe Lancet, 305
W. Poewe, A. Lees, G. Stern (1986)
Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations.Clinical neuropharmacology, 9 5
J. Wagner, P. Vitali, M. Palfreyman, M. Zraika, Stéphane Huot (1982)
Simultaneous Determination of 3,4‐Dihydroxyphenylalanine, 5‐Hydroxytryptophan, Dopamine, 4‐Hydroxy‐3‐Methoxyphenylalanine, Norepinephrine, 3,4‐Dihydroxyphenylacetic Acid, Homovanillic Acid, Serotonin, and 5‐Hydroxyindoleacetic Acid in Rat Cerebrospinal Fluid and Brain by High‐Performance Liquid ChroJournal of Neurochemistry, 38
J. Juncos, C. Serrati, G. Fabbrini, T. Chase (1985)
FLUCTUATING LEVODOPA CONCENTRATIONS AND PARKINSON'S DISEASEThe Lancet, 326
M. Marion, F. Stocchi, N. Quinn, P. Jenner, C. Marsden (1986)
Repeated levodopa infusions in fluctuating Parkinson's disease: clinical and pharmacokinetic data.Clinical neuropharmacology, 9 2
M. Mouradian, J. Juncos, C. Serrati, G. Fabbrini, S. Palmeri, T. Chase (1987)
Exercise and the Antiparkinsonian Response to LevodopaClinical Neuropharmacology, 10
C. Markham, S. Diamond (1986)
Long‐term follow‐up of early dopa treatment in Parkinson's diseaseAnnals of Neurology, 19
R. Hardie, A. Lees, G. Stern (1984)
On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.Brain : a journal of neurology, 107 ( Pt 2)
H. Doller, J. Connor (1980)
Changes in Neostriatal Dopamine Concentrations in Response to Levodopa InfusionsJournal of Neurochemistry, 34
M. Yahr (1977)
LONG-TERM LEVODOPA IN PARKINSON'S DISEASEThe Lancet, 309
Muenter, Tyce Gm (1971)
L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects.Mayo Clinic proceedings, 46 4
S. Fahn (1974)
“On‐off” phenomenon with levodopa therapy in parkinsonismNeurology, 24
R. Lesser, S. Fahn, S. Snider, L. Cote, W. Isgreen, R. Barrett (1979)
Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapyNeurology, 29
B. Bunney, J. Walters, R. Roth, G. Aghajanian (1973)
Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity.The Journal of pharmacology and experimental therapeutics, 185 3
A. Carlsson (1983)
Are "on-off" effects during chronic L-dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway?Journal of neural transmission. Supplementum, 19
S. Ogasahara, Y. Nishikawa, Mitsuo Takahashi, K. Wada, Yusaku Nakamura, S. Yorifuji, S. Tarui (1984)
Dopamine metabolism in the central nervous system after discontinuation of l-dopa therapy in patients with Parkinson diseaseJournal of the Neurological Sciences, 66
MD Fabbrini, MD Juncos, MD Mouradian, MD Serrati, M. Chase (1987)
Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's diseaseAnnals of Neurology, 21
(1979)
Compensatory biochemical changes at the striatal dopamine synapse in Parkinson’s disease-limitations of L-dopa therapy
P. Jenner, M. Sheehy, C. Marsden (1983)
Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson's disease.British journal of clinical pharmacology, 15 Suppl 2
Jl Juncos, Giovanni Fabbrini, M. Mouradian, C. Serrati, A. Kask, Thomas Chase (1987)
Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 50
C. Markham, S. Diamond (1981)
Evidence to support early levodopa therapy in Parkinson diseaseNeurology, 31
M. Hoehn (1983)
Parkinsonism treated with levodopa: progression and mortality.Journal of neural transmission. Supplementum, 19
Wagner Wagner, Vitali Vitali, Palfreyman Palfreyman (1982)
Simultaneous determination of 3,4‐dihydroxyphenylalanine, 5‐hydroxytryptophan, dopamine, 4‐hydroxy‐3‐methoxyphenylalanine, norepinephrine, 3,4‐dihydroxyphenylacetic acid, homovanillic acid, serotonin, and 5‐hydroxyindoleacetic acid in rat cerebrospinal fluid and brain by high‐performance liquid chromatography with electrochemical detectionJ Neurochem, 38
S. Spencer, G. Wooten (1984)
Altered pharmacokinetics of L‐dopa metabolism in rat striatum deprived of dopaminergic innervationNeurology, 34
C. Clough, K. Bergmann, M. Yahr (1984)
Cholinergic and dopaminergic mechanisms in Parkinson's disease after long-term L-DOPA administration.Advances in neurology, 40
Ericksson Ericksson, Magnusson Magnusson, Carlsson Carlsson (1984)
“On‐off” phenomenon in Parkinson's disease: correlation to the concentration of dopa in plasmaJ Neural Transm, 59
K. Shaw, A. Lees, G. Stern (1980)
The impact of treatment with levodopa on Parkinson's disease.The Quarterly journal of medicine, 49 195
K. Leenders, A. Palmer, N. Quinn, J. Clark, G. Firnau, E. Garnett, C. Nahmias, T. Jones, C. Marsden (1986)
Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.Journal of Neurology, Neurosurgery & Psychiatry, 49
N. Quinn, J. Parkes, C. Marsden (1984)
Control of on/off phenomenon by continuous intravenous infusion of levodopaNeurology, 34
C. Marsden, J. Parkes (1976)
"ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPYThe Lancet, 307
R. Kartzinel, D. Calne (1976)
Studies with bromocriptine Part 1. “On‐off” phenomenaNeurology, 26
(1976)
DB: Studies with bromocriptine
J. Nutt, W. Woodward, J. Carter (1986)
Clinical and biochemical studies with controlled‐release levodopa/carbidopaNeurology, 36
J. Grimes, D. King, O. Kofman, P. Molina-Negro, A. Wilson, S. Bouchard (1984)
Bromocriptine in the Management of End of Dose Deterioration in Parkinson’s DiseaseCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 11
Tyrone Lee, P. Seeman, A. Rajput, I. Farley, O. Hornykiewicz (1978)
Receptor basis for dopaminergic supersensitivity in Parkinson's diseaseNature, 273
Hoehn Hoehn, Yahr Yahr (1967)
Parkinsonism: onset, progression and mortalityNeurology, 17
A. Barbeau (1974)
The clinical physiology of side effects in long-term L-DOPA therapy.Advances in neurology, 5
The response to continuous intravenous infusion of levodopa was evaluated in 23 patients with Parkinson's disease complicated by motor fluctuations. Conversion from oral to intravenous levodopa treatment resulted in an immediate and sustained stabilization of plasma levodopa levels in both the wearing‐off and on‐off groups. Motor variability also diminished within the first 24 hours of infusion, although to a much greater extent in patients with the wearing‐off phenomenon. Over the next 5 to 11 days of intravenous treatment, further reductions in motor fluctuations occurred in both groups, at a substantially faster rate in the wearing‐off group than in the on‐off group. The degree of immediate stabilization of parkinsonian motor response correlated best with disease duration, whereas the rate of subsequent improvement correlated most closely with levodopa dose. The results support the view that the wearing‐off phenomenon may reflect the degeneration of dopamine terminals as a consequence of natural disease progression with a resultant inability to buffer variations in levodopa availability; the on‐off phenomenon may reflect additional postsynaptic changes, possibly occurring in response to the nonphysiological fluctuations in synaptic dopamine, which gradually remit during continuous levodopa administration.
Annals of Neurology – Wiley
Published: Oct 1, 1987
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.